Meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at-risk mental states

Psychiatria Danubina

Volumn 22, Issue SUPPL. 1, 2010, Pages

  Kelly, Christopher ^a   Hadjinicolaou, Andreas V ^a   Holt, Clare ^d   Agius, Mark ^b,c   Zaman, Rashid ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BEDFORD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Fundation Programme East Anglian Deanery   (United Kingdom)

Author keywords

Anti depressants; Anti psychotics; At risk mental state; Cognitive behaviour therapy; Omega3 poly unsaturated fatty acids

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; RISPERIDONE;

AKATHISIA; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MENTAL HEALTH; META ANALYSIS; PATIENT COMPLIANCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RIGIDITY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FATTY ACIDS, OMEGA-3; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 78649972525     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Agius M, Bradley V, Ryan D, Zaman R The ethics of identifying and treating psychosis early. Psychiaria Danubina 2008; 20;93-96. (Pubitemid 351513768)
2. Amminger P, Schäfer M, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial Arch Gen Psychiatry. 2010;67(2):146-154.
3. Bechdolf A, et al, "Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state:effects on social adjustment post treatment." Early Intervention in Psychiatry 2007; 1: 71-78.
4. Bentall RP, Morrison AP More harm than good; The case against using antipsychotic drugs to prevent severe mental illness. J Mental Health (2002) 11; 351-356.
5. Berger G, Dell'Olio M, Amminger P, Cornblatt B, Phillips L, Yung A, Yan Y, Berk M, McGorry P, "Neuroprotection in emerging psychotic disorders", Early Intervention in Psychiatry, 2007; 1:114-127.
6. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E, "The Schizophrenia Prodrome Revisited: A Neurodevelopmental Perspective", Schizophrenia Bulletin, 2003; 29:633-651. (Pubitemid 38181947)
7. Comblait BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, et al..Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007; 68:546-57.
8. McGorry, PD, Yung AR, "Randomized Controlled Trial of Interventions Designed to Reduce the Risk of Progression to First-Episode Psychosis in a Clinical Sample With Subthreshold Symptoms", Arch Gen Psychiatry, (2002) Vol 59, 921-928.
9. Morrison AP, Bentall RP, Walford FL, Kilcommons A, Knight A, Kreutz M, Lewis SW, "Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals Study design and interim analysis of transition rate and psychological risk factors", British Journal of Psychiatry, (2002), 181 (suppl. 4 3), s 78- s 84.
10. Morrison AP, French P, Walford L et al. A randomised controlled trial of cognitive therapy for prevention of psychosis in people at ultra-high risk. Schizophrenia Research 2004; 67:7.
11. Nordentoft M, Thorup A, Petersen L, Øhlenschlaeger J, Melau M, Christensen T, Krapup G, Jorgensen P, Jeppesen P, "Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment", Schizophrenia Research, 2006; 83:29-40.
12. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A, "Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis", Am J Psychiatry, 2006; 163:790-799.
13. Ruhrmann S, Bechdolf A, Kühn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Häfner H, Gaebel W, Möller HJ,Maier W, Klosterkötter J; LIPS study group, "Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis", British Journal of Psychiatry, 2007; 191 (suppl. 51), s 88-s 95.
14. Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH.,"Aripiprazole in the treatment of the psychosis prodrome. An open-label pilot study", British Journal of Psychiatry, 2007; 191 (suppl. 51), s96-s101. (Pubitemid 350273196)